1
|
Specker E, Wesolowski R, Schütz A, Matthes S, Mallow K, Wasinska-Kalwa M, Winkler L, Oder A, Alenina N, Pleimes D, von Kries JP, Heinemann U, Bader M, Nazaré M. Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors. J Med Chem 2023; 66:14866-14896. [PMID: 37905925 DOI: 10.1021/acs.jmedchem.3c01454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2023]
Abstract
Tryptophan hydroxylases catalyze the first and rate-limiting step in the biosynthesis of serotonin, a well-known neurotransmitter that plays an important role in multiple physiological functions. A reduction of serotonin levels, especially in the brain, can cause dysregulation leading to depression or insomnia. In contrast, overproduction of peripheral serotonin is associated with symptoms like carcinoid syndrome and pulmonary arterial hypertension. Recently, we developed a class of TPH inhibitors based on xanthine-benzimidazoles, characterized by a tripartite-binding mode spanning the binding sites of the cosubstrate pterin and the substrate tryptophan and by chelation of the catalytic iron ion. Herein, we describe the structure-based development of a second generation of xanthine-imidiazopyridines and -imidazothiazoles designed to inhibit TPH1 in the periphery while preventing the interaction with TPH2 in the brain. Lead compound 32 (TPT-004) shows superior pharmacokinetic and pharmacodynamic properties as well as efficacy in preclinical models of peripheral serotonin attenuation and colorectal tumor growth.
Collapse
Affiliation(s)
- Edgar Specker
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
| | - Radoslaw Wesolowski
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Anja Schütz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Susann Matthes
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Keven Mallow
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Malgorzata Wasinska-Kalwa
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Lars Winkler
- Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Andreas Oder
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Natalia Alenina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany
| | - Dirk Pleimes
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
| | - Jens Peter von Kries
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Udo Heinemann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Michael Bader
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany
- Charité─Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
- University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany
| | - Marc Nazaré
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| |
Collapse
|
2
|
Carkaci-Salli N, Bewley MC, Tekin I, Flanagan JM, Vrana KE. The A328 V/E (rs2887147) polymorphisms in human tryptophan hydroxylase 2 compromise enzyme activity. Biochem Biophys Rep 2023; 35:101527. [PMID: 37608910 PMCID: PMC10440358 DOI: 10.1016/j.bbrep.2023.101527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 08/03/2023] [Accepted: 08/03/2023] [Indexed: 08/24/2023] Open
Abstract
Human tryptophan hydroxylase 2 (hTPH2) is the rate-limiting enzyme for serotonin biosynthesis in the brain. A number of naturally-occurring single nucleotide polymorphisms (SNPs) have been reported for hTPH2. We investigated the activity and kinetic characteristics of the most common missense polymorphism rs2887147 (A328 V/E; 0.92% allelic frequency for the two different reported SNPs at the same site) using bacterially expressed hTPH2. The recombinant full-length enzyme A328E had no measurable enzyme activity, but A328V displayed decreased enzyme activity (Vmax). A328V also displayed substrate inhibition and decreased stability compared to the wild-type enzyme. By contrast, in constructs lacking the N-terminal 150 amino acid regulatory domain, the A328V substitution had no effect; that is, there was no substrate inhibition, enzyme stabilities (for wild-type and A328V) were dramatically increased, and Vmax values were not different (while the A328E variant remained inactive). These findings, in combination with molecular modeling, suggest that substitutions at A328 affect catalytic activity by altering the conformational freedom of the regulatory domain. The reduced activity and substrate inhibition resulting from these polymorphisms may ultimately reduce serotonin synthesis and contribute to behavioral perturbations, emotional stress, and eating disorders.
Collapse
Affiliation(s)
- Nurgul Carkaci-Salli
- Departments of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Maria C. Bewley
- Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Izel Tekin
- Departments of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - John M. Flanagan
- Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Kent E. Vrana
- Departments of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
- Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| |
Collapse
|
3
|
Vallejos-Baccelliere G, Kaufman SB, González-Lebrero RM, Castro-Fernandez V, Guixé V. Characterisation of kinetics, substrate inhibition and product activation by AMP of bifunctional ADP-dependent glucokinase/phosphofructokinase from Methanococcus maripaludis. FEBS J 2022; 289:7519-7536. [PMID: 35717557 DOI: 10.1111/febs.16557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 05/20/2022] [Accepted: 06/16/2022] [Indexed: 01/14/2023]
Abstract
Methanogenic archaea have received attention due to their potential use in biotechnological applications such as methane production, so their metabolism and regulation are topics of special interest. When growing in a nutrient-rich medium, these organisms exhibit gluconeogenic metabolism; however, under starvation conditions, they turn to glycolytic metabolism. To date, no regulatory mechanism has been described for this gluconeogenic/glycolytic metabolic switch. Here, we report that adenosine monophosphate (AMP) activates both enzymatic activities of the bifunctional adenosine diphosphate (ADP)-dependent phosphofructokinase/glucokinase from Methanococcus maripaludis (MmPFK/GK). To understand this phenomenon, we performed a comprehensive kinetic characterisation, including determination of the kinetics, substrate inhibition and AMP activation mechanism of this enzyme. We determined that MmPFK/GK has an ordered-sequential mechanism, in which MgADP is the first substrate to bind and AMP is the last product released. The enzyme also displays substrate inhibition by both sugar substrates; we determined that this inhibition occurs through the formation of catalytically nonproductive enzyme complexes caused by sugar binding. For both activities, the AMP activation mechanism occurs primarily through incremental changes in the affinity for the sugar substrate, with this effect being higher in the GK than in the PFK activity. Interestingly, due to the increase in the sugar substrate affinity caused by AMP, an enhancement in the sugar substrate inhibition effect was also observed for both activities, which can be explained by an increase in sugar binding leading to the formation of dead-end complexes. These results shed light on the regulatory mechanisms of methanogenic archaeal sugar metabolism, a phenomenon that has been largely unexplored.
Collapse
Affiliation(s)
- Gabriel Vallejos-Baccelliere
- Laboratorio de Bioquímica y Biología Molecular, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile
| | - Sergio B Kaufman
- Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - IQUIFIB (UBA-CONICET), Argentina
| | - Rodolfo M González-Lebrero
- Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires - IQUIFIB (UBA-CONICET), Argentina
| | - Víctor Castro-Fernandez
- Laboratorio de Bioquímica y Biología Molecular, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile
| | - Victoria Guixé
- Laboratorio de Bioquímica y Biología Molecular, Departamento de Biología, Facultad de Ciencias, Universidad de Chile, Santiago, Chile
| |
Collapse
|
4
|
Specker E, Matthes S, Wesolowski R, Schütz A, Grohmann M, Alenina N, Pleimes D, Mallow K, Neuenschwander M, Gogolin A, Weise M, Pfeifer J, Ziebart N, Heinemann U, von Kries JP, Nazaré M, Bader M. Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors. J Med Chem 2022; 65:11126-11149. [PMID: 35921615 DOI: 10.1021/acs.jmedchem.2c00598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Tryptophan hydroxylases catalyze the first and rate-limiting step in the synthesis of serotonin. Serotonin is a key neurotransmitter in the central nervous system and, in the periphery, functions as a local hormone with multiple physiological functions. Studies in genetically altered mouse models have shown that dysregulation of peripheral serotonin levels leads to metabolic, inflammatory, and fibrotic diseases. Overproduction of serotonin by tumor cells causes severe symptoms typical for the carcinoid syndrome, and tryptophan hydroxylase inhibitors are already in clinical use for patients suffering from this disease. Here, we describe a novel class of potent tryptophan hydroxylase inhibitors, characterized by spanning all active binding sites important for catalysis, specifically those of the cosubstrate pterin, the substrate tryptophan as well as directly chelating the catalytic iron ion. The inhibitors were designed to efficiently reduce serotonin in the periphery while not passing the blood-brain barrier, thus preserving serotonin levels in the brain.
Collapse
Affiliation(s)
- Edgar Specker
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Susann Matthes
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Radoslaw Wesolowski
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Anja Schütz
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Maik Grohmann
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Natalia Alenina
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany
| | - Dirk Pleimes
- SCINSPIRE Holding & Consulting GmbH, Dunckerstr. 25, 10437 Berlin, Germany
| | - Keven Mallow
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Martin Neuenschwander
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Angelina Gogolin
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Marie Weise
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Jochen Pfeifer
- Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Nandor Ziebart
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Freie Universität Berlin, Chemistry and Biochemistry Institute, Takustr. 3, 14195 Berlin, Germany
| | - Udo Heinemann
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,Freie Universität Berlin, Chemistry and Biochemistry Institute, Takustr. 3, 14195 Berlin, Germany
| | - Jens Peter von Kries
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Marc Nazaré
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Michael Bader
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany.,University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany.,Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
5
|
Protective Role of Melatonin and Its Metabolites in Skin Aging. Int J Mol Sci 2022; 23:ijms23031238. [PMID: 35163162 PMCID: PMC8835651 DOI: 10.3390/ijms23031238] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/19/2022] [Accepted: 01/20/2022] [Indexed: 02/01/2023] Open
Abstract
The skin, being the largest organ in the human body, is exposed to the environment and suffers from both intrinsic and extrinsic aging factors. The skin aging process is characterized by several clinical features such as wrinkling, loss of elasticity, and rough-textured appearance. This complex process is accompanied with phenotypic and functional changes in cutaneous and immune cells, as well as structural and functional disturbances in extracellular matrix components such as collagens and elastin. Because skin health is considered one of the principal factors representing overall “well-being” and the perception of “health” in humans, several anti-aging strategies have recently been developed. Thus, while the fundamental mechanisms regarding skin aging are known, new substances should be considered for introduction into dermatological treatments. Herein, we describe melatonin and its metabolites as potential “aging neutralizers”. Melatonin, an evolutionarily ancient derivative of serotonin with hormonal properties, is the main neuroendocrine secretory product of the pineal gland. It regulates circadian rhythmicity and also exerts anti-oxidative, anti-inflammatory, immunomodulatory, and anti-tumor capacities. The intention of this review is to summarize changes within skin aging, research advances on the molecular mechanisms leading to these changes, and the impact of the melatoninergic anti-oxidative system controlled by melatonin and its metabolites, targeting the prevention or reversal of skin aging.
Collapse
|
6
|
Annunziato M, Eeza MNH, Bashirova N, Lawson A, Matysik J, Benetti D, Grosell M, Stieglitz JD, Alia A, Berry JP. An integrated systems-level model of the toxicity of brevetoxin based on high-resolution magic-angle spinning nuclear magnetic resonance (HRMAS NMR) metabolic profiling of zebrafish embryos. THE SCIENCE OF THE TOTAL ENVIRONMENT 2022; 803:149858. [PMID: 34482148 DOI: 10.1016/j.scitotenv.2021.149858] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 08/18/2021] [Accepted: 08/19/2021] [Indexed: 06/13/2023]
Abstract
Brevetoxins (PbTx) are a well-recognized group of neurotoxins associated with harmful algal blooms, and specifically recurrent "Florida Red Tides," in marine waters that are linked to impacts on both human and ecosystem health including well-documented "fish kills" and marine mammal mortalities in affected coastal waters. Understanding mechanisms and pathways of PbTx toxicity enables identification of relevant biomarkers to better understand these environmental impacts, and improve monitoring efforts, in relation to this toxin. Toward a systems-level understanding of toxicity, and identification of potential biomarkers, high-resolution magic angle spinning nuclear magnetic resonance (HRMAS NMR) was utilized for metabolic profiling of zebrafish (Danio rerio) embryos, as an established toxicological model, exposed to PbTx-2 (the most common congener in marine waters). Metabolomics studies were, furthermore, complemented by an assessment of the toxicity of PbTx-2 in embryonic stages of zebrafish and mahi-mahi (Coryphaena hippurus), the latter representing an ecologically and geographically relevant marine species of fish, which identified acute embryotoxicity at environmentally relevant (i.e., parts-per-billion) concentrations in both species. HRMAS NMR analysis of intact zebrafish embryos exposed to sub-lethal concentrations of PbTx-2 afforded well-resolved spectra, and in turn, identification of 38 metabolites of which 28 were found to be significantly altered, relative to controls. Metabolites altered by PbTx-2 exposure specifically included those associated with (1) neuronal excitotoxicity, as well as associated neural homeostasis, and (2) interrelated pathways of carbohydrate and energy metabolism. Metabolomics studies, thereby, enabled a systems-level model of PbTx toxicity which integrated multiple metabolic, molecular and cellular pathways, in relation to environmentally relevant concentrations of the toxin, providing insight to not only targets and mechanisms, but potential biomarkers pertinent to environmental risk assessment and monitoring strategies.
Collapse
Affiliation(s)
- Mark Annunziato
- Institute of Environment, Department of Chemistry and Biochemistry, Florida International University, 3000 NE 151st Street, North Miami, FL 33181, USA
| | - Muhamed N H Eeza
- Institute of Medical Physics and Biophysics, University of Leipzig, Leipzig, Germany; Institute for Analytical Chemistry, University of Leipzig, Leipzig, Germany
| | - Narmin Bashirova
- Institute of Medical Physics and Biophysics, University of Leipzig, Leipzig, Germany; Institute for Analytical Chemistry, University of Leipzig, Leipzig, Germany
| | - Ariel Lawson
- Institute of Environment, Department of Chemistry and Biochemistry, Florida International University, 3000 NE 151st Street, North Miami, FL 33181, USA
| | - Jörg Matysik
- Institute for Analytical Chemistry, University of Leipzig, Leipzig, Germany
| | - Daniel Benetti
- Rosenstiel School of Marine and Atmospheric Sciences, University of Miami, Miami, FL, USA
| | - Martin Grosell
- Rosenstiel School of Marine and Atmospheric Sciences, University of Miami, Miami, FL, USA
| | - John D Stieglitz
- Rosenstiel School of Marine and Atmospheric Sciences, University of Miami, Miami, FL, USA
| | - A Alia
- Institute of Medical Physics and Biophysics, University of Leipzig, Leipzig, Germany; Leiden Institute of Chemistry, Leiden University, 2333 Leiden, the Netherlands.
| | - John P Berry
- Institute of Environment, Department of Chemistry and Biochemistry, Florida International University, 3000 NE 151st Street, North Miami, FL 33181, USA; Biomolecular Science Institute, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
| |
Collapse
|
7
|
Kim TK, Atigadda VR, Brzeminski P, Fabisiak A, Tang EKY, Tuckey RC, Reiter RJ, Slominski AT. Detection of Serotonin, Melatonin, and Their Metabolites in Honey. ACS FOOD SCIENCE & TECHNOLOGY 2021; 1:1228-1235. [PMID: 35449872 PMCID: PMC9017714 DOI: 10.1021/acsfoodscitech.1c00119] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Melatonin and serotonin, products of tryptophan metabolism, are endogenous neurotransmitters and hormones. We have identified and quantified these metabolites in natural honey from Australia, USA, and Poland using a Xevo G2 XS qTof LC-MS. To help ensure correct product identification, some samples were prepurified by RP-HPLC based on the retention times of standards, prior to LC-MS. The concentrations of the metabolites of interest depended on the source of the honey. For Australian honey, levels for melatonin and 2-hydroxymelatonin were 0.91 and 0.68 ng/g, respectively. Melatonin was detected in one brand of US commercial honey at 0.48 ng/g, while a second brand contained serotonin at 88.2 ng/g. In Polish natural honey, 20.6 ng/g of serotonin and 40.8 ng/g of N-acetylserotonin (NAS) were detected, while in Polish commercial honey 25.9 ng/g of serotonin and 7.30 ng/g of NAS were present. We suggest that addictive and health-related properties of honey may be in part dependent on the presence of serotonin, melatonin, and their metabolites, and that these compounds may play a role in the colony activities of bees.
Collapse
Affiliation(s)
- Tae-Kang Kim
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States; VA Medical Center, Birmingham, Alabama 35294, United States
| | - Venkatram R Atigadda
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
| | - Pawel Brzeminski
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States; Department of Chemistry, University of Warsaw, 02-093 Warsaw, Poland
| | - Adrian Fabisiak
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States; Department of Chemistry, University of Warsaw, 02-093 Warsaw, Poland
| | - Edith K Y Tang
- School of Molecular Sciences, The University of Western Australia, Perth, Western Australia 6009, Australia
| | - Robert C Tuckey
- School of Molecular Sciences, The University of Western Australia, Perth, Western Australia 6009, Australia
| | - Russel J Reiter
- Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, Texas 77030, United States
| | - Andrzej T Slominski
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States; VA Medical Center, Birmingham, Alabama 35294, United States
| |
Collapse
|
8
|
Kokkonen P, Beier A, Mazurenko S, Damborsky J, Bednar D, Prokop Z. Substrate inhibition by the blockage of product release and its control by tunnel engineering. RSC Chem Biol 2021; 2:645-655. [PMID: 34458806 PMCID: PMC8341658 DOI: 10.1039/d0cb00171f] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Accepted: 12/17/2020] [Indexed: 11/21/2022] Open
Abstract
Substrate inhibition is the most common deviation from Michaelis-Menten kinetics, occurring in approximately 25% of known enzymes. It is generally attributed to the formation of an unproductive enzyme-substrate complex after the simultaneous binding of two or more substrate molecules to the active site. Here, we show that a single point mutation (L177W) in the haloalkane dehalogenase LinB causes strong substrate inhibition. Surprisingly, a global kinetic analysis suggested that this inhibition is caused by binding of the substrate to the enzyme-product complex. Molecular dynamics simulations clarified the details of this unusual mechanism of substrate inhibition: Markov state models indicated that the substrate prevents the exit of the halide product by direct blockage and/or restricting conformational flexibility. The contributions of three residues forming the possible substrate inhibition site (W140A, F143L and I211L) to the observed inhibition were studied by mutagenesis. An unusual synergy giving rise to high catalytic efficiency and reduced substrate inhibition was observed between residues L177W and I211L, which are located in different access tunnels of the protein. These results show that substrate inhibition can be caused by substrate binding to the enzyme-product complex and can be controlled rationally by targeted amino acid substitutions in enzyme access tunnels.
Collapse
Affiliation(s)
- Piia Kokkonen
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
| | - Andy Beier
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
- International Clinical Research Center, St. Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic
| | - Stanislav Mazurenko
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
| | - Jiri Damborsky
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
- International Clinical Research Center, St. Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic
| | - David Bednar
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
- International Clinical Research Center, St. Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic
| | - Zbynek Prokop
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University Kamenice 5/A13 625 00 Brno Czech Republic
- International Clinical Research Center, St. Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic
| |
Collapse
|
9
|
Groaz A, Galvan S, Valer L, Rossetto D, Benedetti F, Guella G, Toparlak ÖD, Mansy SS. Cell-Free Synthesis of Dopamine and Serotonin in Two Steps with Purified Enzymes. ACTA ACUST UNITED AC 2020; 4:e2000118. [PMID: 33107224 DOI: 10.1002/adbi.202000118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 10/14/2020] [Indexed: 01/05/2023]
Abstract
The synthesis of serotonin and dopamine with purified enzymes is described. Both pathways start from an amino acid substrate and synthesize the monoamine neurotransmitter in two enzymatic steps. The enzymes human tryptophan hydroxylase isoform 2, Rattus norvegicus tyrosine hydroxylase, Chlamydia pneumoniae Cpn1046, and aromatic amino acid decarboxylase from Drosophila melanogaster are recombinantly expressed, purified, and shown to be functional in vitro. The hydroxylases efficiently convert L-DOPA (L-dihydroxy-phenylalanine) and 5-HTP (5-hydroxytryptophan) from L-tyrosine and L-tryptophan, respectively. A single aromatic amino acid decarboxylase is capable of converting both hydroxylated intermediates into the final neurotransmitter. The platform described here may facilitate future efforts to generate medically useful artificial cells and nanofactories.
Collapse
Affiliation(s)
- Alessandro Groaz
- CIBIO, University of Trento, Via Sommarive 9, Trento, 38123, Italy
| | - Silvia Galvan
- CIBIO, University of Trento, Via Sommarive 9, Trento, 38123, Italy
| | - Luca Valer
- CIBIO, University of Trento, Via Sommarive 9, Trento, 38123, Italy
| | - Daniele Rossetto
- CIBIO, University of Trento, Via Sommarive 9, Trento, 38123, Italy
| | | | - Graziano Guella
- Department of Physics, University of Trento, Via Sommarive 14, Trento, 38123, Italy
| | | | - Sheref S Mansy
- CIBIO, University of Trento, Via Sommarive 9, Trento, 38123, Italy.,Department of Chemistry, University of Alberta, 11227 Saskatchewan Dr, Edmonton, AB, T6G 2G2, Canada
| |
Collapse
|
10
|
Szőke H, Kovács Z, Bókkon I, Vagedes J, Szabó AE, Hegyi G, Sterner MG, Kiss Á, Kapócs G. Gut dysbiosis and serotonin: intestinal 5-HT as a ubiquitous membrane permeability regulator in host tissues, organs, and the brain. Rev Neurosci 2020; 31:415-425. [DOI: 10.1515/revneuro-2019-0095] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 12/16/2019] [Indexed: 12/12/2022]
Abstract
AbstractThe microbiota and microbiome and disruption of the gut-brain axis were linked to various metabolic, immunological, physiological, neurodevelopmental, and neuropsychiatric diseases. After a brief review of the relevant literature, we present our hypothesis that intestinal serotonin, produced by intestinal enterochromaffin cells, picked up and stored by circulating platelets, participates and has an important role in the regulation of membrane permeability in the intestine, brain, and other organs. In addition, intestinal serotonin may act as a hormone-like continuous regulatory signal for the whole body, including the brain. This regulatory signal function is mediated by platelets and is primarily dependent on and reflects the intestine’s actual health condition. This hypothesis may partially explain why gut dysbiosis could be linked to various human pathological conditions as well as neurodevelopmental and neuropsychiatric disorders.
Collapse
Affiliation(s)
- Henrik Szőke
- Department of CAM, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
- Doctorate School, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
| | - Zoltán Kovács
- Doctorate School, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
| | - István Bókkon
- Vision Research Institute, Neuroscience and Consciousness Research Department, Lowell, MA, USA
- Psychosomatic Outpatient Clinics, Budapest, Hungary
| | - Jan Vagedes
- University of Tübingen, Children’s Hospital, Tübingen, Germany
- ARCIM Institute (Academic Research in Complementary and Integrative Medicine), Filderstadt, Germany
| | | | - Gabriella Hegyi
- Department of CAM, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
- Doctorate School, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
| | | | - Ágnes Kiss
- Doctorate School, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
| | - Gábor Kapócs
- Buda Family-Centered Mental Health Centre, Department of Psychiatry and Psychiatric Rehabilitation, Teaching Department of Semmelweis University, New Saint John Hospital, Budapest, Hungary
- Institute for Behavioral Sciences, Semmelweis University, Budapest, Hungary
| |
Collapse
|
11
|
Slominski AT, Kim TK, Kleszczyński K, Semak I, Janjetovic Z, Sweatman T, Skobowiat C, Steketee JD, Lin Z, Postlethwaite A, Li W, Reiter RJ, Tobin DJ. Characterization of serotonin and N-acetylserotonin systems in the human epidermis and skin cells. J Pineal Res 2020; 68:e12626. [PMID: 31770455 PMCID: PMC7007327 DOI: 10.1111/jpi.12626] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 11/15/2019] [Accepted: 11/16/2019] [Indexed: 12/14/2022]
Abstract
Tryptophan hydroxylase (TPH) activity was detected in cultured epidermal melanocytes and dermal fibroblasts with respective Km of 5.08 and 2.83 mM and Vmax of 80.5 and 108.0 µmol/min. Low but detectable TPH activity was also seen in cultured epidermal keratinocytes. Serotonin and/or its metabolite and precursor to melatonin, N-acetylserotonin (NAS), were identified by LC/MS in human epidermis and serum. Endogenous epidermal levels were 113.18 ± 13.34 and 43.41 ± 12.45 ng/mg protein for serotonin (n = 8/8) and NAS (n = 10/13), respectively. Their production was independent of race, gender, and age. NAS was also detected in human serum (n = 13/13) at a concentration 2.44 ± 0.45 ng/mL, while corresponding serotonin levels were 295.33 ± 17.17 ng/mL (n = 13/13). While there were no differences in serum serotonin levels, serum NAS levels were slightly higher in females. Immunocytochemistry studies showed localization of serotonin to epidermal and follicular keratinocytes, eccrine glands, mast cells, and dermal fibrocytes. Endogenous production of serotonin in cultured melanocytes, keratinocytes, and dermal fibroblasts was modulated by UVB. In conclusion, serotonin and NAS are produced endogenously in the epidermal, dermal, and adnexal compartments of human skin and in cultured skin cells. NAS is also detectable in human serum. Both serotonin and NAS inhibited melanogenesis in human melanotic melanoma at concentrations of 10-4 -10-3 M. They also inhibited growth of melanocytes. Melanoma cells were resistant to NAS inhibition, while serotonin inhibited cell growth only at 10-3 M. In summary, we characterized a serotonin-NAS system in human skin that is a part of local neuroendocrine system regulating skin homeostasis.
Collapse
Affiliation(s)
- Andrzej T. Slominski
- Department of Dermatology, University of Alabama at Birmingham, and Birmingham, AL, USA
- Department of Dermatology,VA Medical Center; Birmingham, AL, USA
| | - Tae-Kang Kim
- Department of Dermatology, University of Alabama at Birmingham, and Birmingham, AL, USA
| | - Konrad Kleszczyński
- Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, Germany
| | - Igor Semak
- Department of Biochemistry, Belarusian State University, Minsk, Belarus
| | - Zorica Janjetovic
- Department of Dermatology, University of Alabama at Birmingham, and Birmingham, AL, USA
| | | | - Cezary Skobowiat
- Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
| | | | - Zongtao Lin
- Departments of Pharmaceutical Sciences, Memphis, TN 38163, USA
| | - Arnold Postlethwaite
- Departments of Medicine, Division of Rheumatology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
- Departments of VA Medical Center, Memphis, TN 38163, USA
| | - Wei Li
- Departments of Pharmaceutical Sciences, Memphis, TN 38163, USA
| | - Russel J. Reiter
- Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, TX, USA
| | - Desmond J. Tobin
- The Charles Institute of Dermatology, University College Dublin, Dublin, Ireland
| |
Collapse
|
12
|
Paley EL, Perry G. Towards an Integrative Understanding of tRNA Aminoacylation-Diet-Host-Gut Microbiome Interactions in Neurodegeneration. Nutrients 2018; 10:nu10040410. [PMID: 29587458 PMCID: PMC5946195 DOI: 10.3390/nu10040410] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 03/19/2018] [Accepted: 03/22/2018] [Indexed: 02/07/2023] Open
Abstract
Transgenic mice used for Alzheimer’s disease (AD) preclinical experiments do not recapitulate the human disease. In our models, the dietary tryptophan metabolite tryptamine produced by human gut microbiome induces tryptophanyl-tRNA synthetase (TrpRS) deficiency with consequent neurodegeneration in cells and mice. Dietary supplements, antibiotics and certain drugs increase tryptamine content in vivo. TrpRS catalyzes tryptophan attachment to tRNAtrp at initial step of protein biosynthesis. Tryptamine that easily crosses the blood–brain barrier induces vasculopathies, neurodegeneration and cell death via TrpRS competitive inhibition. TrpRS inhibitor tryptophanol produced by gut microbiome also induces neurodegeneration. TrpRS inhibition by tryptamine and its metabolites preventing tryptophan incorporation into proteins lead to protein biosynthesis impairment. Tryptophan, a least amino acid in food and proteins that cannot be synthesized by humans competes with frequent amino acids for the transport from blood to brain. Tryptophan is a vulnerable amino acid, which can be easily lost to protein biosynthesis. Some proteins marking neurodegenerative pathology, such as tau lack tryptophan. TrpRS exists in cytoplasmic (WARS) and mitochondrial (WARS2) forms. Pathogenic gene variants of both forms cause TrpRS deficiency with consequent intellectual and motor disabilities in humans. The diminished tryptophan-dependent protein biosynthesis in AD patients is a proof of our model-based disease concept.
Collapse
Affiliation(s)
- Elena L Paley
- Expert Biomed, Inc., 11933 SW 271st TER Homestead, Miami Dade, FL 33032-3305, USA.
- Stop Alzheimers Corp., Miami Dade, FL 33032, USA.
- Nova Southeastern University, 3301 College Ave, Fort Lauderdale, FL 33314, USA.
| | - George Perry
- Stop Alzheimers Corp., Miami Dade, FL 33032, USA.
- University of Texas at San Antonio, 1 UTSA Circle, San Antonio, TX 78249, USA.
| |
Collapse
|